Cells, compositions and therapeutic compositions

By enriching mononuclear cells with CD14(+)CD206(+)CXCR4(+) cells using specific growth factors, a cell group with enhanced vascular regeneration and wound healing abilities is produced, addressing inefficiencies in existing EPC culturing methods and offering effective treatments for ischemic and inflammatory conditions.

JP7595864B2Active Publication Date: 2024-12-09JUNTENDO EDUCATIONAL FOUNDATION +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2020120876
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-14
Publication Date
2024-12-09
Estimated Expiration
2040-07-14

AI Technical Summary

Technical Problem

Existing methods for culturing vascular endothelial progenitor cells (EPCs) are inefficient and do not fully harness the therapeutic potential of CD14(+)CD206(+)CXCR4(+) cells for treating ischemic diseases and inflammatory conditions.

Method used

Culturing mononuclear cells from bone marrow, umbilical cord blood, or peripheral blood using a medium containing factors like stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and vascular endothelial growth factor to enrich for CD14(+)CD206(+)CXCR4(+) cells, which are then selectively recovered to form a cell group with enhanced vascular regeneration and wound healing abilities.

Benefits of technology

The CD14(+)CD206(+)CXCR4(+) cell group demonstrates superior angiogenic and wound healing capabilities, providing effective therapeutic compositions for ischemic diseases and inflammatory wounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595864000002
    Figure 0007595864000002
  • Figure 0007595864000003
    Figure 0007595864000003
  • Figure 0007595864000004
    Figure 0007595864000004
Patent Text Reader

Abstract

To provide a cell, a composition, and a composition for treatment.SOLUTION: Inventive cells are CD14(+) CD206(+) CXCR4(+). The inventive cell group comprises 40% or more of the cells: CD14(+) CD206(+) CXCR4(+). The inventive composition for treatment comprises the cells or cell group and is used to treat ischemic disease, inflammatory disease or refractory wound.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a cell and a composition. The cells of the present invention are characterized by being CD14(+)CD206(+)CXCR4(+). The cell population of the present invention is a cell population containing 40% or more of the cells of the present invention. The present invention also relates to a composition for treating ischemic disease, inflammatory disease, or difficult-to-heal wounds, comprising the cells or cell population of the present invention. [Background technology]

[0002] In recent years, cell transplantation therapy using bone marrow mononuclear cell transplantation therapy and endothelial progenitor cells (EPCs) obtained by peripheral blood stem cell collection has been performed for ischemic diseases. Therefore, there has been a particular demand for a technique for mass-culturing EPCs. A method for ex vivo expansion of endothelial progenitor cells from CD34 and / or CD133 positive cells has made it possible to provide an efficient EPC culture technique (Patent Document 1). Furthermore, a method for analyzing the kinetics of endothelial cell differentiation has revealed the existence of endothelial cell-like large colony-forming cells (differentiated EPC colonies) and endothelial cell-like small colony-forming cells (undifferentiated EPC colonies), making it possible to predict and understand the therapeutic effect of cell transplantation (Patent Document 2). In addition, a method for efficiently expanding CD34 and / or CD133 positive cells from bone marrow mononuclear cells has been shown (Patent Document 3).

[0003] As shown in International Publication WO2014 / 051154, a method for expanding a cell population enriched in vascular endothelial progenitor cells or anti-inflammatory / immune tolerance-inducing cells from a mononuclear cell fraction derived from bone marrow, umbilical cord blood, or peripheral blood (hereinafter, sometimes referred to as the "QQ-MNC method") has been described. This method involves culturing mononuclear cells in a serum-free medium containing five factors, namely (1) stem cell factor (SCF), (2) interleukin-6 (IL-6), (3) FMS-like tyrosine kinase 3 ligand (FL), (4) thrombopoietin (TPO), and (5) vascular endothelial growth factor (VEGF), thereby expanding a cell population containing EPCs ex vivo. As a result of further intensive research efforts, as shown in Patent Application No. 2019-231606 (unpublished), the inventors have succeeded in obtaining a new cell population that has vascular regeneration and wound healing capabilities and is different from the cell population shown in International Publication WO2014 / 051154, by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a medium containing four or less factors selected from the group consisting of stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial growth factor, and serum. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication WO2006 / 090882 [Patent Document 2] International Publication WO2006 / 090886 [Patent Document 3] International Publication WO2006 / 093172 [Patent Document 4] International Publication WO2014 / 051154 Summary of the Invention [Problem to be solved by the invention]

[0005] As a result of conducting research into the cell group shown in Patent Application No. 2019-231606 (unpublished), the inventors discovered CD14(+)CD206(+)CXCR4(+) cells and a cell group that contains a large amount of said cells, and found that said cells and a cell group that contains a large amount of said cells have even superior vascular regeneration and wound healing abilities, which led to the invention of the present application.

[0006] The present invention provides cells that are CD14(+)CD206(+)CXCR4(+). The present invention also provides a cell population containing 40% or more CD14(+)CD206(+)CXCR4(+) cells.

[0007] The present invention also provides a composition for treating ischemic disease, inflammatory disease or difficult-to-heal wounds, which comprises the cells or cell groups of the present invention. [Means for solving the problem]

[0008] The present invention includes, but is not limited to, the following aspects. [Aspect 1] Cells that are CD14(+)CD206(+)CXCR4(+). [Aspect 2] A cell population comprising 40% or more of the cells of embodiment 1. [Aspect 3] A cell population according to aspect 2, wherein CD14(+)CD206(+)CXCR4(-) cells account for 20% or less. [Aspect 4] A composition for treating an ischemic disease, an inflammatory disease or a difficult-to-heal wound, comprising the cells according to aspect 1 or the cell group according to aspect 2 or 3. [Aspect 5] The therapeutic composition according to aspect 4, wherein the ischemic disease is limb ischemia. [Aspect 6] The therapeutic composition according to aspect 4 or 5, wherein the ischemic disease is limb ischemia accompanied by ulcer. [Aspect 7] 7. The therapeutic composition according to any one of aspects 4-6, which promotes angiogenesis and / or wound healing. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 shows an example of a flow cytometry (FACS) scatter plot used to gate cell populations in the area containing Rema cells prepared from peripheral blood of a healthy individual. [Diagram 2] FIG. 2 shows micrographs of human umbilical vein endothelial cells (HUVEC) with lumen-forming ability co-cultured with Rema cells and non-Rema cells. [Diagram 3] Figure 3 shows the effect of co-culturing human umbilical vein endothelial cells (HUVECs) with Rema cells and non-Rema cells. Figure 3A shows the number of lumens formed, and Figure 3B shows the number of fluorescently labeled Rema cells and non-Rema cells incorporated into the luminal structure. [Figure 4] FIG. 4 is a schematic diagram showing an outline of an experiment to examine wound healing ability. [Diagram 5] Figure 5 shows the results of investigating the effect of co-culturing Rema cells and non-Rema cells with fibroblasts on fibroblast migration, i.e., wound contraction. Photographs were taken 0, 6, 12, and 24 hours after cell co-cultivation using the fully automated high-throughput live cell analysis system IncuCyte (registered trademark) S3. [Figure 6] FIG. 6 shows the wound reduction rate after 6, 12, and 24 hours, calculated from the wound area in the photograph of FIG. 5 using IncuCyte (registered trademark) cell migration software. [Figure 7] FIG. 7 is a micrograph of human umbilical vein endothelial cells (HUVEC) having lumen formation ability co-cultured with Rema cells. [Figure 8] FIG. 8 shows the effect of co-culturing human umbilical vein endothelial cells (HUVEC) having lumen-forming ability with Rema cells in terms of the number of lumen formed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] 1.Cells In one aspect, the present invention relates to a cell. The cell of the present invention is characterized in that it is CD14(+)CD206(+)CXCR4(+).

[0011] CD14 is one of the components of the innate immune system observed in humans, mice, etc. CD14 acts as a coreceptor (together with TLR4 or MD-2) and recognizes lipopolysaccharide (LPS) derived from bacteria.

[0012] CD206 (also known as MMR, CLEC13D, MRC1) is a type I membrane receptor with a multilectin receptor structure. CD206 mediates the uptake and endocytosis of proteins containing glycans by macrophages. CD206 has been shown to bind to high mannose structures on the surface of potentially pathogenic viruses, bacteria, and fungi, which are eliminated by phagocytosis.

[0013] CXCR4 (also known as CD184) is a G protein-coupled receptor (GPCR) that spans the cell membrane seven times. The physiological ligand for CXCR4 is stromal cell-derived factor-1 (SDF-1), a CXC chemokine. CXCR4 is relatively widely distributed in the body and is expressed on a variety of CD4(+) cells in the immune and central nervous systems. In the blood, CD184 cells are highly expressed on neutrophils, monocytes, dendritic cells, NK cells, B cells, T cells, and platelets.

[0014] The sequences and structures of the proteins and genes of CD14, CD206, and CXCR4 are known, and whether each is co-positive, i.e., CD14(+), CD206(+), or CXCR4(+), can be examined by known methods. Without being limited thereto, the presence of the proteins CD14, CD206, and CXCR4 can be confirmed, for example, by a substance that specifically binds to these proteins, such as an antibody, a ligand, and the like. For example, the following are known as antibodies specific to each of them:

[0015] CD14-specific antibody: APC-Cy7-anti-human CD14 antibody (BioLegend) CD206-specific antibody: PE-cy7-anti-human CD206 antibody (BioLegend) CXCR4-specific antibody: APC-anti-human CXCR4 antibody (BioLegend) These antibodies can be used to confirm the presence or absence of these proteins by, for example, fluorescent antibody techniques, and CD14(+), CD206(+), and CXCR4(+) cells can be sorted by, for example, flow cytometry or magnetic collection using microbead labeling. Alternatively, the presence or absence of nucleic acid for CD14, CD206, or CXCR4 may be confirmed using methods such as polymerase chain reaction (PCR) or RNA sequencing (RNA-Seq).

[0016] 2.Cell group In one aspect, the present invention relates to a population of cells.

[0017] The cell population comprises cells that are CD14(+)CD206(+)CXCR4(+). In one embodiment (i.e., without limitation), the cell population comprises 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, or 98% or more of cells that are CD14(+)CD206(+)CXCR4(+).

[0018] The proportion of CD14(+)CD206(+)CXCR4(+) cells in a cell population can be determined by known methods. For example, it can be determined by flow cytometry that a cell population contains 40% or more CD14(+)CD206(+)CXCR4(+) cells.

[0019] In one embodiment (i.e., without limitation), the percentage of CD14(+)CD206(+)CXCR4(-) cells is 40% or less, 30% or less, 20% or less, 10% or less, 5% or less. The percentage of CD14(+)CD206(+)CXCR4(-) cells can be determined by methods similar to those described above for the percentage of cells that are CD14(+)CD206(+)CXCR4(+).

[0020] 3. Method for obtaining cells or cell groups There are no particular limitations on the method for obtaining the above-mentioned CD14(+)CD206(+)CXCR4(+) cells or a cell population containing CD14(+)CD206(+)CXCR4(+) cells.

[0021] In one embodiment, a cell population containing CD14(+)CD206(+)CXCR4(+) cells or CD14(+)CD206(+)CXCR4(+) cells is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood, or peripheral blood. The "mononuclear cells" used to obtain the above cell population is a general term for cells with round nuclei contained in peripheral blood, bone marrow, umbilical cord blood, etc., and includes lymphocytes, monocytes, macrophages, vascular endothelial precursor cells, hematopoietic stem cells, etc. For example, bone marrow, umbilical cord blood, or peripheral blood is collected from an animal, and mononuclear cells are obtained by, for example, using a blood collection tube for mononuclear cell separation or by subjecting the blood to density gradient centrifugation to extract the fraction. The density gradient centrifugation method is not particularly limited as long as a mononuclear cell fraction is formed. For example, Histopaque-1077 (Sigma-Aldrich) may be used.

[0022] The animal species from which the bone marrow, umbilical cord blood or peripheral blood is derived is not particularly limited. The animal species includes general mammals including humans to which cell transplantation therapy is applied for diseases such as ischemic disease, inflammatory disease, or intractable wounds. In view of the purpose of clinical application, humans are preferred.

[0023] In one embodiment, CD14(+)CD206(+)CXCR4(+) cells are obtained by (i) culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a medium containing five factors, namely stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial growth factor, or three or four factors selected from these five factors, and serum or a serum-free medium, and (ii) selectively recovering CD14(+)CD206(+)CXCR4(+).

[0024] Furthermore, a cell population containing CD14(+)CD206(+)CXCR4(+) cells can be obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a medium containing five factors, namely stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial growth factor, or three or four factors selected from these five factors, and serum or a medium not containing serum.

[0025] Stem cell factor (SCF) is a glycoprotein consisting of 248 amino acids and having a molecular weight of about 30,000. Although there are soluble and membrane-bound forms due to selective splicing, any type of SCF may be used to obtain the above cell group as long as it is useful for culturing mononuclear cells. The soluble type is preferable. The origin of SCF is not particularly limited. Recombinant forms that are expected to be supplied stably are preferable, and human recombinant forms are particularly preferable. Commercially available SCFs are known. The concentration of SCF in the culture medium varies depending on the type of SCF used, and is not particularly limited as long as it is useful for culturing mononuclear cells. In the case of human recombinant SCF, the concentration is not particularly limited, for example, 10 to 1000 ng / mL, preferably 50 to 500 ng / mL, and more preferably about 100 ng / mL.

[0026] Interleukin 6 (IL-6) is a glycoprotein with a molecular weight of 210,000 that was isolated as a factor that induces the final differentiation of B cells into antibody-producing cells. IL-6 is generally known to be involved in immune responses, proliferation and differentiation of hematopoietic and nervous system cells, acute phase reactions, and the like. The IL-6 used to obtain the above cell group is not particularly limited and is appropriately selected. When used to culture human monocytes, human IL-6 is preferred, and recombinant IL-6, which is expected to be supplied stably, is particularly preferred. Commercially available IL-6 is known. The concentration of IL-6 in the culture medium varies depending on the type of IL-6 used, and is not particularly limited as long as it is useful for culturing monocytes. In the case of human recombinant IL-6, the concentration is, for example, 1 to 500 ng / mL, preferably 5 to 100 ng / mL, and more preferably about 20 ng / mL, but is not limited thereto.

[0027] FMS-like tyrosine kinase 3 ligand (FL) is known as a ligand of receptor tyrosine kinase that plays an important role in early hematopoietic control. Several alternative splicing products are known, and it has been reported that FL stimulates the proliferation of hematopoietic stem cells. The FL used to obtain the above cell group may be any type of FL as long as it is useful for culturing mononuclear cells. Commercially available FLs are known. The concentration of FL in the culture medium varies depending on the type of FL used, and is not particularly limited as long as it is useful for culturing mononuclear cells. In the case of human recombinant Flt-3 ligand, the concentration is, for example, 10 to 1000 ng / mL, preferably 50 to 500 ng / mL, and more preferably about 100 ng / mL.

[0028] Thrombopoietin (TPO) is a type of hematopoietic cytokine, and is known to act specifically on the process of producing megakaryocytes from hematopoietic stem cells and promote the production of megakaryocytes. The origin of TPO used to obtain the above cell group is not particularly limited. Recombinants that are expected to be stably supplied are preferred, and human recombinants are particularly preferred. Commercially available TPOs are known. The concentration of TPO in the culture medium varies depending on the type of TPO used and is not particularly limited as long as it is useful for culturing mononuclear cells, but in the case of human recombinant TPO, it is, for example, 1 to 500 ng / mL, preferably 5 to 100 ng / mL, and more preferably about 20 ng / mL.

[0029] Vascular endothelial growth factor (VEGF) is a growth factor that acts specifically on endothelial progenitor cells (EPCs), and is known to be produced mainly in cells surrounding blood vessels. Several types of VEGF proteins with different sizes are produced by selective splicing, and the VEGF used to obtain the above cell group may be any type of VEGF as long as it enables colony formation of EPCs. VEGF165 is preferable. The origin of VEGF is not particularly limited. Recombinants that are expected to be supplied stably are preferable, and human recombinants are particularly preferable. Commercially available VEGFs are known. The concentration of VEGF in the culture medium varies depending on the type of VEGF used, and is not particularly limited as long as it is useful for culturing mononuclear cells. In the case of human recombinant VEGF165, the concentration is, for example, about 5 to 500 ng / mL, preferably about 20 to 100 ng / mL, and more preferably about 50 ng / mL.

[0030] Various factors added to the culture medium used for culturing mononuclear cells may also be standardized to factors derived from the same species of animal as the animal from which the mononuclear cells are derived, without being limited thereto. By standardizing the origin of the mononuclear cells and various factors in this way, a cell culture suitable for allogeneic transplantation such as allogeneic transplantation can be obtained. In addition, by using mononuclear cells derived from an individual intended for cell transplantation, it is also possible to obtain a cell culture suitable for allogeneic transplantation.

[0031] The above-mentioned components can be dissolved in a culture medium to a predetermined concentration, or a concentrated solution (stock solution) of each component can be prepared in advance and diluted with a culture medium to a predetermined concentration to prepare a culture medium for culturing mononuclear cells. For example, the components necessary for a commercially available culture medium can be dissolved to a predetermined concentration and then sterilized by filtration sterilization or the like, or a stock solution sterilized by filtration sterilization or the like can be aseptically added to a commercially available culture medium and diluted to prepare a culture medium. Filtration sterilization can be performed according to a method commonly used in the art, for example, using a 0.22 μm or 0.45 μm Millipore filter or the like.

[0032] The "culture medium" used in the present invention may be a medium commonly used in the art, for example, a culture medium known as a medium for the proliferation of hematopoietic stem cells. Examples of basal media used as culture media include Stemline II, DMEM, MEM, IMDM, RPMI, SCGM, EBM, etc.

[0033] In order to obtain the above cells and cell groups, the medium for culturing mononuclear cells contains five factors, namely stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial growth factor, or three or four factors selected from these five factors, as well as a medium containing or not containing serum.

[0034] The type of serum is not particularly limited. In one embodiment, but not limited to, the serum is bovine or human serum. In one embodiment, the serum may include both bovine and human serum. In one embodiment, the serum is fetal bovine serum. The concentration of serum in the medium is also not particularly limited. In one embodiment, the serum is contained in the medium at 0.1% by volume or more, 0.3% by volume or more, or 0.5% by volume or more. There is no particular upper limit to the concentration of serum in the medium. In one embodiment, the serum is contained within 30% by volume or less, 20% by volume or less, 10% by volume or less, or 5% by volume or less. In one embodiment, the serum is contained within the medium at a concentration of 0.1% by volume or more to 20% by volume, or 0.5% by volume or more to 10% by volume.

[0035] The mononuclear cell culture is carried out by adding a cell suspension containing mononuclear cells to a medium containing the above-mentioned factors and serum or a medium not containing serum. As the cell suspension, a body fluid containing mononuclear cells (e.g., bone marrow fluid, umbilical cord blood, peripheral blood) itself can also be used. The conditions for culturing mononuclear cells are not particularly limited, and the culture can be carried out under conditions that are usually used in the field. For example, the mononuclear cells are cultured at about 37°C under a 5% CO2 atmosphere. The culture period is, for example, not limited to, 3 days or more, 5 days or less, 6 days or less, 7 days or less, or 10 days or less. For example, 3 days to 10 days, or 3 days to 6 days. The concentration of mononuclear cells in the medium is not particularly limited as long as it allows the culture of mononuclear cells, but may be, for example, about 0.1 to 10 × 10 6 cells / ml, more preferably about 0.5-5×10 6 cells / ml.

[0036] "Selectively recovering CD14(+)CD206(+)CXCR4(+)" can be achieved by selectively recovering (sorting) CD14(+)CD206(+)CXCR4(+) cells, i.e., cells containing CD14, CD206, and CXCR4, by appropriately using the method for confirming the presence of CD14, CD206, and CXCR4 described in "1. Cells." For example, flow cytometry using substances that specifically bind to these proteins, such as antibodies and ligands, magnetic recovery using microbead labels, etc. can be used. The above-mentioned method is one example for obtaining the above-mentioned cells and cell populations.

[0037] 4. Therapeutic composition In one aspect, the present invention relates to a composition for treating ischemic disease, inflammatory disease, or difficult-to-treat wounds. The therapeutic composition of the present invention contains the cells and cell groups described in "1. Cells" and "2. Cell groups." The cells and cell groups may be derived from the subject who will use the therapeutic composition (autologous) or may be derived from a subject other than the subject who will use the therapeutic composition (allogeneic).

[0038] "Ischemic disease" is a disease caused by tissue damage such as cell degeneration, atrophy, and fibrosis due to a decrease in blood volume, which reduces blood flow in tissue. Ischemia is broadly classified into obstructive ischemia, compressive ischemia, convulsive ischemia, and compensatory ischemia depending on the cause. If ischemia continues, cell degeneration, atrophy, and fibrosis occur. "Ischemic disease" includes limb ischemia, ischemic ulcer, ischemic heart disease, cerebral infarction, ischemic enteritis, ischemic hepatitis, ischemic kidney damage, and the like. "Cerebral infarction" (or cerebral softening) is classified as cerebral thrombosis and cerebral embolism, which refers to cerebral ischemia caused by blockage or narrowing of the artery that nourishes the brain, resulting in cerebral ischemia, and brain tissue becomes necrotic or in a state close to necrosis due to lack of oxygen or nutrients. "Limb ischemia" is a disease in which the arteries supplying blood to the limbs are narrowed or blocked, and when this obliterative arteriosclerosis becomes severe or due to collagen disease, severe limb ischemia occurs, causing symptoms such as pain and intractable ulcers, and in the worst case, amputation may be required. In one embodiment, the limb is, but is not limited to, the lower limb.

[0039] In one non-limiting embodiment, the ischemic disease is limb ischemia. The ischemic disease is limb ischemia accompanied by ulcers. "Inflammatory disease" is a general term for diseases that cause symptoms due to abnormalities such as tissue damage caused by some cause. Inflammatory diseases include Crohn's disease, liver cirrhosis, hepatitis, ulcerative colitis, inflammatory bowel disease, etc.

[0040] The therapeutic composition promotes angiogenesis and / or wound healing. Therefore, it can be applied to diseases treatable by angiogenesis and / or wound healing. Examples of "diseases treatable by angiogenesis and / or wound healing" include ischemic diseases (e.g., myocardial infarction, ischemic heart disease such as angina pectoris, lower limb ischemia such as lower limb ischemic arteriosclerosis, Burger's disease), and vascular damage. It can also be used to heal wounds such as skin ulcers, or to prepare artificial blood vessels. The effect of applying the therapeutic composition can be confirmed by a method known per se. For example, when the disease treatable by angiogenesis is lower limb ischemic disease, the therapeutic effect after transplantation can be evaluated, for example, by examining the lower limb blood flow and the necrosis improvement rate. The increase in blood flow can be measured by measuring the value of laser Doppler imaging analysis. The necrosis improvement rate can also be measured visually as a limb salvage score.

[0041] The mode of use of the above-mentioned therapeutic composition is not particularly limited. It may be a cell group or cell group itself as an active ingredient, or the cell or cell group may be suspended in a liquid medium. The liquid medium may be any liquid that can be injected into humans, for example, isotonic electrolyte infusion, phosphate buffer, physiological saline, or serum-free medium such as DMEM. The liquid medium may also contain a compound that is favorable for cell survival, such as albumin. In addition, when frozen and stored, it may be suspended in a frozen cell storage solution or the like.

[0042] The subject to which the therapeutic composition is applied is not particularly limited as long as it is a subject that requires treatment of an ischemic disease, an inflammatory disease, or a wound that is difficult to treat, and includes, but is not limited to, humans, monkeys, chimpanzees, dogs, cats, cows, horses, mice, guinea pigs, etc.

[0043] 4.Treatment method etc. In one aspect, the present invention relates to a method for treating an ischemic disease, an inflammatory disease, or a difficult-to-heal wound, comprising applying the cells or cell groups described in "1. Cells" or "2. Cell groups" to a subject in need thereof.

[0044] In one aspect, the present invention relates to the use of the cells or cell groups described in "1. Cells" or "2. Cell groups" in a method for treating ischemic disease, inflammatory disease or difficult-to-treat wounds, which includes applying the cells or cell groups to a subject in need thereof, or to the use of the cells or cell groups in a composition for treating ischemic disease, inflammatory disease or difficult-to-treat wounds.

[0045] In one aspect, the present invention relates to the cells or cell groups described in "1. Cells" and "2. Cell groups" for use in a method for treating ischemic disease, inflammatory disease, or difficult-to-heal wounds. The "ischemic disease", "inflammatory disease" or "difficult-to-treat wound", "application mode of the cell group", "target of application", etc. are as described in "3. Therapeutic composition". EXAMPLES

[0046] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. Those skilled in the art can easily modify and alter the present invention based on the description in this specification, and such modifications and alterations are within the technical scope of the present invention.

[0047] Example 1 Isolation of Rema cells (1) Isolation of mononuclear cells 100 mL of peripheral blood was collected from healthy volunteers using a BD Vacutainer (registered trademark) CPT (trademark) blood collection tube for mononuclear cell separation (BD). After blood collection, the blood collection tube was centrifuged as is, and then transported and stored in a refrigerator until the start of culture after arrival. The part above the gel barrier in the CPT (trademark) blood collection tube containing mononuclear cells and plasma was collected in a centrifuge tube, and the inside of the blood collection tube, including the part above the gel barrier, was washed with a small amount of EDTA-PBS and collected in the same centrifuge tube. The centrifuge tube in which the cells were collected was filled with EDTA-PBS, and then centrifuged (300 x g, room temperature, 15 minutes) to collect the cells as a sediment. The collected cells were incubated in ACK hemolysis buffer (15 mL / tube) (Gibco, Thermo-Fisher) at room temperature for 5 minutes to remove contaminating red blood cells. The composition of the ACK hemolysis buffer was NH4Cl 8,290 mg / L, KHCO3 1,000 mg / L, EDTA.Na2·2H2O 37 mg / L. The cells were then collected twice by centrifugation (200xg, room temperature, 10 min) or (100xg, room temperature, 15 min).

[0048] (2) Culture in serum-free medium The collected mononuclear cells were suspended in 1 mL of growth medium, and a portion of the suspension was used to count the number of cells using trypan blue. The cells were cultured in several growth media as shown below. Medium 1 was stemline (registered trademark) II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, Cat No. S0192) supplemented with 50 ng / mL VEGF, 100 ng / mL SCF, 100 ng / mL Flt-3 ligand, 20 ng / mL TPO, 20 ng / mL and IL-6, 100 units / mL of five factors, as well as penicillin and 100 μg / mL streptomycin.

[0049] In the resulting cell growth medium, the cell concentration was increased to 1x10 6The cells were prepared at a concentration of 100 / mL and 2 mL of each solution was seeded into each well of a 6-well culture plate. They were cultured for 5 days under normal culture conditions (37°C, 5% CO2). After the 5-day culture, the cells were collected into a centrifuge tube and centrifuged three times at 250xg (~1000 rpm) for 7-10 minutes. After centrifugation, the remaining cells, except for the samples for cell count, viability measurement, and QC (confirmation) test, were suspended in PlasmaLyte A and 2.5% human albumin serum and diluted to 8x10 5 The concentration was adjusted to cells / mL.

[0050] (3) Flow cytometry analysis In this example, flow cytometry analysis was performed on the cell population obtained by the above-mentioned culture to determine the content of CD14(+)CD206(+)CXCR4(+) cells and CD14(+)CD206(+)CXCR4(-) cells.

[0051] Cells (1.5 × 10 ) were suspended in FACS buffer (composition: 2 mM EDTA-PBS supplemented with 2% FBS). 6 To the aliquots (cells / 300 μL-FACS buffer), 10 μL of FACS blocking reagent (Miltenyi) was added and incubated at 4°C for 30 minutes. After incubation, the cell groups were dispensed into equal amounts into staining reaction tubes (100 μL / tube x 3 tubes). 2 μL of each primary antibody was added to each aliquot and incubated at 4°C for 20 minutes. After that, the cells were washed twice with 1 mL of FACS buffer, and the stained cells were suspended in FACS buffer (5 × 10 5 (cells / 200 to 300 μL-FACS buffer) Flow cytometry was performed using a BD FACSAria (trademark) III cell sorter (manufactured by BD).

[0052] Specifically, the expression of each cell surface marker in the obtained cell population was examined using antibodies against each cell surface marker. The antibodies against each cell surface marker were all commercially available as follows.

[0053] Anti-CD206 antibody: PE / Cy7-labeled anti-human CD206 (MMR) antibody (BioLegend); Anti-CXCR4 antibody: APC-labeled anti-human CD184 (CXCR4) antibody (BD), Anti-CD14 antibody: APC-Cy7-anti-human CD14 antibody (BioLegend). Cells that are CD14(+)CD206(+)CXCR4(+) are sometimes called "Rema cells", and cells that are CD14(+)CD206(+)CXCR4(-) are sometimes called "Non-Rema cells". This cell group contained 33.34% Rema cells and 28.17% non-Rema cells.

[0054] (4) Isolation of Rema cells and non-Rema cells In this example, CD14(+)CD206(+)CXCR4(+) Rema cells and CD14(+)CD206(+)CXCR4(-) Non-Rema cells were isolated from the culture medium cultured from the mononuclear cells obtained by the above-mentioned method.

[0055] After cell counting, 1 × 10 cells were placed in a 50 mL centrifuge tube. 7 The cells were suspended in FACS buffer (composition: 2 mM EDTA-PBS containing 2% FBS) at a cell / 300 μL. 7 FcR blocking reagent (Miltenyi Biotec) was added at 20 μL per cell, and the mixture was incubated at 4° C. for 10 minutes.

[0056] PEcy7-anti-human CD206 antibody (BioLegend) and APC-anti-human CXCR4 antibody (BioLegend) were each added at 1 × 10 7 Before staining with the above two antibodies, 2 to 5 × 10 cells / 400 μL of isotype control, CD206 single stain, and CXCR4 single stain were added to adjust the sorting settings. 5 The cells were separated into 1.5 mL tubes and stained.

[0057] After addition of the antibody, the mixture was incubated at 4°C for 30 minutes. FACS buffer was added to make 50 mL, and the mixture was centrifuged (250 G x 10 minutes, 4°C). The supernatant was aspirated, and the mixture was diluted with FACS buffer to 1 x 10 7 The cells were suspended in 3 mL of cells, transferred to a 5 mL tube with a cell strainer (for flow cytometer, Corning, NY, USA), and adjusted. Flow cytometry was performed using a BD FACSAria (trademark) III cell sorter (BD).

[0058] The CD206-positive and CXCR4-positive fraction was defined as Rema cells, and the CD206-positive and CXCR4-negative fraction was defined as Non-Rema cells. As the initial sorting setting, dead cells were removed by DAPI staining, and the cell population in the area containing the target cells (Figure 1) was gated. Doublets were removed from the lower layer of the gated area, and the spillover of the fluorescent dye was adjusted using an isotype control and a single-stained sample.

[0059] Example 2 Effect of Rema cells (1) Angiogenic potential of Rema cells In this example, the angiogenic ability of the Rema cells isolated in Example 1 was examined.

[0060] Human umbilical vein endothelial cells (HUVEC) with lumen formation ability (obtained from Lonza, Basel, Switzerland) were used at passages 8 to 10, and each group of cells was co-cultured with HUVEC. Basement membrane matrix (Corning (registered trademark) Matrigel (registered trademark) (Corning, NY, USA)) was dispensed at 50 μl / well into a 96-well plate and coated at 37°C for 30 minutes. Meanwhile, the ReMa cells isolated in Example 2 were suspended in 500 μl of IMDM + 5 μl of DiI-Ac-LDL for labeling with DiI-Ac-LDL, and incubated at 37°C for 1 hour. As a comparative example, non-Rema cells prepared in Example 1 were used.

[0061] After labeling, Rema cells or non-Rema cells were cultured at 1x10 3 / 25μl and 5x10 HUVECs3 Each was resuspended in PBS to a volume of 25 μl / well. The suspension with the adjusted cell number was mixed with the Rema cell group and HUVEC at a 1:1 ratio, and 50 μl of each was added onto the Matrigel. The cells were cultured at 37°C and 5% CO2 for 3 to 5 hours. After culture, the number of lumens formed and the number of fluorescently labeled cells (Rema cells or non-Rema cells) incorporated into the luminal structure were visually counted at 100x magnification using an IX83 fluorescent microscope (Olympus).

[0062] The results are shown in Figures 2 and 3. Figure 2 shows micrographs of HUVECs alone (control group), Rema cell co-culture, and non-Rema cell co-culture. Figure 3A shows the number of lumens formed, and Figure 3B shows the number of fluorescently labeled Rema cells and non-Rema cells incorporated into the luminal structure. As shown in Figure 3, it was revealed that Rema cells have higher in vitro blood vessel formation ability than the control group and non-Rema cells. It was also revealed that Rema cells are incorporated into the luminal structure more than non-Rema cells.

[0063] (2) Wound healing ability of Rema cells In this example, the wound healing ability of the Rema cells obtained in Example 1 was examined. As a comparative example, non-Rema cells (CD14(+)CD206(+)CXCR4(-)) were used. The outline of the experiment is shown in FIG.

[0064] Human skin-derived fibroblasts were prepared after 6 to 10 passages in culture medium (DMEM containing 10% FBS). The prepared fibroblasts were placed in 96-well IncuCyte® ImageLock Plates (Essen BioScience, Ann Arbor, MI, USA) at 0.8 x 10 4 Rema cells, non-Rema cells, or both were seeded at a density of 0.8x10 cells / well. 4The cells were added at a density of 100 cells / well using culture inserts so as not to come into contact with the fibroblasts. They were co-cultured at 37°C for 24 hours in DMEM medium containing 0.5% FBS.

[0065] Scratch wounds were created using the 96-well Wound Maker tool of the IncuCyte® scratch assay. Cells were washed with PBS to remove dead cells. Photographs were taken at 0, 6, 12, and 24 hours after cell co-culture using the fully automated high-throughput live cell analysis system IncuCyte® S3. The results are shown in Figure 5. Furthermore, the wound area was calculated using the IncuCyte® cell migration software. Figure 6 shows the reduction rate of the wound after 6, 12, and 24 hours, with the time at 0 being set as 0. As is clear from FIG. 6, Rema cells showed a higher wound healing ability than non-Rema cells at all times after 6, 12, and 24 hours.

[0066] Example 3 Cultivation of a cell population rich in Rema cells In this example, mononuclear cells were isolated from peripheral blood, and a cell population rich in Rema cells was cultured.

[0067] (1) Isolation of mononuclear cells 100 mL of peripheral blood was collected from diabetic volunteers using a BD Vacutainer (registered trademark) CPT (trademark) (BD) blood collection tube for mononuclear cell separation. The blood collection method and the method for isolating mononuclear cells were the same as those in Example 1 (1).

[0068] (2) Culture in serum-containing medium The collected mononuclear cells were suspended in 1 mL of growth medium, and a portion of the suspension was used to count the number of cells using trypan blue. The cells were cultured in the following growth media. Medium 1 was prepared by adding five factors, namely, 50 ng / ml VEGF, 100 ng / ml SCF, 100 ng / ml Flt-3 ligand, 20 ng / ml TPO, 20 ng / ml IL-6, and 100 units / ml, as well as penicillin, 100 μg / ml streptomycin, and 0.5% FBS, and was prepared by adding stemline (registered trademark) II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, Cat No. S0192). Medium 2 was prepared by adding three factors, namely, 50 ng / ml VEGF, 100 ng / ml Flt-3 ligand, 20 ng / ml TPO, and 20 ng / ml, as well as penicillin, 100 μg / ml streptomycin, and 0.5% FBS, and was prepared by adding stemline (registered trademark) II Hematopoietic Stem Cell Expansion Medium (Sigma-Aldrich, Cat No. S0192). Medium 3 was Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 50 ng / ml VEGF, 100 ng / ml Flt-3 ligand, 20 ng / ml TPO, 20 ng / ml three factors, as well as penicillin, 100 μg / mL streptomycin, 0.5% FBS, and 0.5% human albumin serum.

[0069] In the resulting cell growth medium, the cell concentration was increased to 1x10 6 The cells were prepared at a concentration of 100 / mL and 2 mL of each solution was seeded into each well of a 6-well culture plate. They were cultured for 5 days under normal culture conditions (37°C, 5% CO2). After the 5-day culture, the cells were collected into a centrifuge tube and centrifuged three times at 250xg (~1000 rpm) for 7-10 minutes. After centrifugation, the remaining cells, except for the samples for cell count, viability measurement, and QC (confirmation) test, were suspended in PlasmaLyte A and 2.5% human albumin serum and diluted to 8x10 5 The concentration was adjusted to cells / mL.

[0070] (3) Flow cytometry analysis In this example, the cell population obtained by the above-mentioned culture was subjected to flow cytometry analysis in order to clarify the content of CD14(+)CD206(+)CXCR4(+) cells therein.

[0071] The method is the same as in Example 1. The percentages of Rema cells and non-Rema cells in the cell populations cultured in each medium are shown in Table 1.

[0072] [Table 1]

[0073] Example 4 Effect of cell groups rich in Rema cells (1) Angiogenic potential of cell groups rich in Rema cells In this example, the angiogenic potential of a cell population containing a large number of Rema cells (Rema cell group) obtained using the above-mentioned medium 2 was examined. The method for testing the angiogenic potential was the same as in Example 2.

[0074] The results are shown in Figures 7 and 8. Figure 7 is a micrograph of the co-culture of HUVEC and Rema cell group. Figure 8 shows the number of lumens formed. As shown in Figure 8, it was revealed that the Rema cell group has higher in vitro blood vessel formation ability compared to the control group (HUVEC only).

[0075] (2) Effect of Rema cells on a mouse hindlimb ischemia model In this example, the effect of the cell population containing a large number of Rema cells (Rema cell group) obtained in Example 3 on a mouse hindlimb ischemia model was examined.

[0076] A lower limb ischemia model was created under general inhalation anesthesia using immunodeficient BALB / cAJcl-nu / nu nude mice (obtained from Japan CLEA). Specifically, the inguinal skin of immunodeficient mice under general inhalation anesthesia was incised and the inguinal fat tissue was removed. The femoral artery immediately below the incision site was ligated with 6-0 silk thread, and the downstream saphenous artery was cauterized and cut with a bipolar.

[0077] The Rema cell group obtained with medium 2 in Example 3 was transplanted intramuscularly at 4 ischemic sites at a concentration of 2,500 cells / site. As a comparative example, a group administered with physiological saline was used. After transplantation, macroscopic observation and blood flow measurement by laser Doppler were performed over time. After the observation, the number of blood vessels and the number of anti-inflammatory macrophages were counted by tissue immunostaining, and the tissue regeneration effect by cell transplantation was confirmed. [Industrial Applicability]

[0078] The present invention provides new cells or cell groups with high vascular regeneration and wound healing capabilities. The cells or cell groups of the present invention can be used, for example, as a therapeutic agent for patients with intractable lower limb ischemia. This can bring about life innovation, such as improving patient QOL and reducing the burden of care, by, for example, making it possible to avoid lower limb amputation, and is of great social significance. Furthermore, the provision of novel cells or cell groups can lead to the establishment of new treatment strategies and provide insight into vascular lesions in general.

Claims

1. A composition for treating an ischemic disease, an inflammatory disease, or a difficult-to-treat wound, comprising a cell population containing 40% or more cells that are CD14(+)CD206(+)CXCR4(+), The cell population is obtained by (i) culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood, and (ii) selectively recovering cells that are CD14(+)CD206(+)CXCR4(+). The therapeutic composition.

2. A composition for treating ischemic disease, inflammatory disease, or difficult-to-treat wounds, comprising a cell population containing 80% or more cells that are CD14(+)CD206(+)CXCR4(+).

3. The therapeutic composition described in claim 2, wherein the cell population comprises 20% or less CD14(+)CD206(+)CXCR4(-) cells.

4. The therapeutic composition according to any one of claims 1 to 3, wherein the ischemic disease is limb ischemia.

5. The therapeutic composition according to any one of claims 1 to 4, wherein the ischemic disease is limb ischemia accompanied by ulcer.

6. A therapeutic composition according to any one of claims 1 to 5, which promotes angiogenesis and / or wound healing.

Citation Information

Patent Citations

  • Multicolor Flow Cytometry Method for Identifying Cell Populations in Specific Mesenchymal Stem Cells

    JP2016519938A

  • Method for amplification of endothelial progenitor cell in vitro

    WO2006090882A1

  • Method of analyzing dynamics in the differentiation of vascular endothelial progenitor cells

    WO2006090886A1

  • Method for in vitro amplification of adult stem cells

    WO2006093172A1

  • Method for in vitro proliferation of cell population containing cells suitable for treatment of ischemic disease

    WO2014051154A1